- Home
- OCFC vs ELVN Comparison
OCFC vs ELVN Comparison
Compare OCFC & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- ELVN
- Stock Information
- Founded
- OCFC 1902
- ELVN 2016
- Country
- OCFC United States
- ELVN United States
- Employees
- OCFC N/A
- ELVN N/A
- Industry
- OCFC Major Banks
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- ELVN Health Care
- Exchange
- OCFC Nasdaq
- ELVN Nasdaq
- Market Cap
- OCFC 861.7M
- ELVN 842.4M
- IPO Year
- OCFC 1996
- ELVN 2020
- Fundamental
- Price
- OCFC $16.50
- ELVN $18.30
- Analyst Decision
- OCFC Buy
- ELVN Strong Buy
- Analyst Count
- OCFC 4
- ELVN 4
- Target Price
- OCFC $21.75
- ELVN $39.25
- AVG Volume (30 Days)
- OCFC 331.8K
- ELVN 361.8K
- Earning Date
- OCFC 04-24-2025
- ELVN 05-13-2025
- Dividend Yield
- OCFC 4.84%
- ELVN N/A
- EPS Growth
- OCFC N/A
- ELVN N/A
- EPS
- OCFC 1.65
- ELVN N/A
- Revenue
- OCFC $375,233,000.00
- ELVN N/A
- Revenue This Year
- OCFC N/A
- ELVN N/A
- Revenue Next Year
- OCFC $12.62
- ELVN N/A
- P/E Ratio
- OCFC $10.01
- ELVN N/A
- Revenue Growth
- OCFC N/A
- ELVN N/A
- 52 Week Low
- OCFC $14.03
- ELVN $13.30
- 52 Week High
- OCFC $21.87
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- OCFC 54.23
- ELVN 49.78
- Support Level
- OCFC $15.59
- ELVN $15.44
- Resistance Level
- OCFC $16.93
- ELVN $19.61
- Average True Range (ATR)
- OCFC 0.78
- ELVN 1.95
- MACD
- OCFC 0.18
- ELVN 0.21
- Stochastic Oscillator
- OCFC 83.71
- ELVN 74.18
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.